Adding weekly semaglutide to insulin therapy in a type 1 diabetes patient produced 12 kg weight loss, 15% body fat reduction, and improved glucose control in just 2 months.
-12 kg in 2 monthssemaglutide added to insulin in type 1 diabetes also reduced body fat 15%, visceral fat 7%, and improved HbA1c and glucose variability
What the researchers found
In a 34-year-old woman with 23 years of type 1 diabetes, adding semaglutide (1 mg weekly) to insulin therapy produced dramatic improvements in just 2 months: 12 kg weight loss (63→51 kg), 15% reduction in body fat percentage, 7% decrease in visceral fat, reduced HbA1c (from 8.3%), lower insulin doses, and decreased glycemic variability.
Why it matters
GLP-1 receptor agonists are not approved for type 1 diabetes, yet many T1D patients struggle with weight gain and glucose instability on insulin alone. This case shows that semaglutide may be a valuable adjunct in T1D — addressing multiple problems simultaneously (weight, body composition, glucose control, insulin requirements) — and could prompt formal clinical trials in this population.
The numbers in context
Weight: 63→51 kg (-12 kg) · body fat: -15% · visceral fat: -7% · HbA1c from 8.3% · BMI from 26.9 · semaglutide 1 mg weekly · 2-month results
How the study worked
Single case report. A 34-year-old woman with longstanding T1DM (23 years) was started on subcutaneous semaglutide 1 mg weekly as an adjunct to existing insulin therapy. Weight, body composition (body fat %, visceral fat), HbA1c, glycemic variability, and insulin dose were assessed at baseline and after 2 months.
Who was studied
Single 34-year-old woman with 23-year history of type 1 diabetes
What this study cannot tell us
Single case report (n=1) — cannot be generalized. Two months is very short follow-up. The 12 kg weight loss in 2 months is unusually rapid and may not be sustainable. Risk of diabetic ketoacidosis (DKA) from insulin reduction in T1D was not discussed. Published in Cureus (lower-impact journal). No control or comparison period.
How to read the evidence
Single case report — the lowest level of clinical evidence. While the results are dramatic, this cannot be generalized without controlled trials. The rapid weight loss and off-label use in T1D require careful scrutiny regarding safety, particularly DKA risk.
When this study was published
Published in 2024, this case report reflects growing clinical interest in using GLP-1 peptide drugs off-label in type 1 diabetes, an area where formal clinical trial evidence is still developing.
The bigger picture
The expanding applications of GLP-1 peptide drugs continue to surprise. While semaglutide is well-established for type 2 diabetes and obesity, its potential in type 1 diabetes is largely unexplored. T1D patients increasingly face weight issues (partly from insulin therapy), and GLP-1 drugs could address this while also improving glucose stability through slowed gastric emptying and glucagon suppression. This case adds momentum to calls for formal clinical trials of GLP-1 agonists in T1D.
Questions still open
- Does semaglutide increase the risk of diabetic ketoacidosis in type 1 diabetes patients who reduce their insulin dose?
- Would a randomized trial of semaglutide as T1D adjunct therapy confirm these dramatic body composition improvements?
- Is the rapid 12 kg weight loss in 2 months safe and sustainable, or does it indicate excessive caloric restriction?
Common questions
Why isn't semaglutide approved for type 1 diabetes?
Is losing 12 kg in 2 months on semaglutide normal?
Read the original research
Rapid Improvement in Weight, Body Composition, and Glucose Variability With Semaglutide in Type 1 Diabetes.
Cureus, 16(6), e61577
Citation
Gad, Hoda; Malik, Rayaz A. (2024). Rapid Improvement in Weight, Body Composition, and Glucose Variability With Semaglutide in Type 1 Diabetes.. Cureus, 16(6), e61577. https://doi.org/10.7759/cureus.61577